Oregano Oil

Metadata

Approved Indications

Commission E (Germany)

• No Commission E monograph exists specifically for oregano essential oil as an oral supplement
• Commission E has a monograph for oregano herb (Origani vulgaris herba) for respiratory catarrh, but this refers to the dried herb, not the concentrated essential oil

ESCOP

• No ESCOP monograph has been published for oregano oil

EMA/HMPC (European Medicines Agency)

• No EMA/HMPC monograph exists for oregano oil
• The EMA has not assessed oregano oil as a traditional herbal medicinal product

Agreement/Disagreement Between Bodies

• No regulatory body has issued a monograph for oregano essential oil as an oral supplement
• The distinction between oregano herb (dried plant material used as tea or spice) and oregano essential oil (concentrated volatile oil) is critical — regulatory assessments of the herb do not automatically apply to the essential oil
• The absence of monographs reflects the lack of clinical evidence, not necessarily a negative safety assessment

Conditions Treated

Primary (Strong In Vitro Evidence, Limited Clinical Evidence)

• Antimicrobial / Immune support: Broad-spectrum antimicrobial activity against Gram-positive and Gram-negative bacteria, fungi (Candida spp.), and some parasites is well-documented in vitro. Clinical evidence in humans is very limited
• Small intestinal bacterial overgrowth (SIBO): One clinical study (Chedid et al. 2014) included oregano oil as part of a multi-herb protocol that was equivalent to rifaximin; oregano oil was not studied in isolation

Secondary (Preclinical Evidence, No Robust Clinical Data)

• Upper respiratory infections: Popular supplement for cold and flu prevention/treatment; relies primarily on in vitro antimicrobial data and traditional use rather than clinical trials
• Gut dysbiosis / Intestinal parasites: Small open-label study (Force et al. 2000) showed clearance of enteric parasites; requires confirmation in controlled trials
• Candidal infections: Strong in vitro antifungal activity; clinical data is absent

Traditional/Historical (Limited Evidence)

• Digestive complaints and bloating (historical use of oregano herb as a carminative)
• Cough and bronchitis (traditional use in Mediterranean folk medicine)
• Topical antiseptic for minor wounds and skin infections
• Toothache and oral infections (historical folk remedy)
• Food preservation (well-established antimicrobial use in food science)

Mechanism of Action

Primary Mechanisms

Antimicrobial (Carvacrol and Thymol):

• Carvacrol and thymol disrupt bacterial cell membrane integrity by inserting into the lipid bilayer, increasing membrane permeability, and causing leakage of intracellular contents (ATP, ions, proteins)
• Both compounds inhibit biofilm formation and can disrupt pre-formed biofilms
• Carvacrol depolarizes the cytoplasmic membrane and inhibits ATPase activity
• Synergistic effects with conventional antibiotics have been demonstrated in vitro, particularly with aminoglycosides and polymyxins

Antifungal:

• Disruption of fungal cell membrane by interaction with ergosterol (similar to azole antifungals)
• Inhibition of hyphal morphogenesis in Candida albicans
• Prevention of fungal biofilm formation

Secondary Mechanisms

Important Caveat: In Vitro vs. In Vivo

• The antimicrobial concentrations achievable in vitro are substantially higher than those achievable in human tissues after oral ingestion
• Carvacrol is rapidly absorbed and metabolized, with peak plasma levels after oral administration typically well below MIC values demonstrated in vitro
• The direct application model (essential oil in contact with pathogen on agar plate) does not reflect the pharmacokinetics of oral supplementation
• This pharmacokinetic gap is the primary reason why in vitro potency has not translated into robust clinical evidence

Clinical Evidence Summary

Volume of Evidence

• Very limited. Despite enormous in vitro research output, human clinical trial evidence is extremely sparse. The disconnect between research popularity and clinical trial output is one of the most striking in the herbal supplement field.

Key Studies

Antimicrobial / SIBO

Safety / Pharmacokinetics

What the Evidence Does NOT Show

• No placebo-controlled RCTs exist for oregano oil monotherapy for any indication
• No studies have demonstrated clinical efficacy for cold/flu prevention or treatment
• No clinical trials support the popular claim that oregano oil is a “natural antibiotic” in the human body
• No dose-response data from human studies

Evidence Gaps

• No placebo-controlled RCTs for any indication
• No pharmacokinetic studies defining achievable tissue concentrations after oral dosing
• No studies comparing oregano oil with standard antimicrobial treatments
• No long-term safety data beyond 6 weeks
• No studies defining optimal dose for any clinical indication
• The critical gap between in vitro MIC values and achievable human tissue concentrations has not been bridged

European vs US/Anglophone Consensus

Safety Profile

Contraindications

• Known hypersensitivity to oregano, carvacrol, thymol, or other Lamiaceae plants
• Active gastric or duodenal ulcers (essential oil may irritate damaged mucosa)
• Iron deficiency (oregano oil may reduce iron absorption)
• Surgery (discontinue at least 2 weeks before surgery due to potential anticoagulant effects)

Drug Interactions

• No clinically documented drug interactions at standard supplement doses
• Theoretical interaction with anticoagulant/antiplatelet drugs (carvacrol has demonstrated antiplatelet activity in vitro)
• Theoretical interaction with antidiabetic medications (carvacrol has shown hypoglycemic effects in animal models)
• May reduce iron absorption; separate from iron supplements by at least 2 hours

Side Effects

• Gastrointestinal: Heartburn, nausea, and gastric irritation are the most commonly reported adverse effects, particularly with undiluted or high-dose oil
• Oral/esophageal irritation: Direct contact of undiluted essential oil with oral or esophageal mucosa can cause burning sensation and irritation
• Allergic reactions: Contact dermatitis possible with topical use; cross-reactivity with other Lamiaceae plants (thyme, basil, mint)
• Die-off reactions: Some practitioners report Herxheimer-like reactions when oregano oil is used for gut dysbiosis; this is poorly documented and may simply reflect gastrointestinal irritation

Pregnancy/Lactation

• Not recommended in pregnancy: Oregano oil has traditional emmenagogue properties; carvacrol has demonstrated uterine stimulant effects in animal models. Culinary amounts of dried oregano herb are considered safe
• Lactation: Insufficient data; not recommended during breastfeeding in supplement doses
• Not recommended for children under 12 years in essential oil form

General Safety Note

• Essential oil supplementation is fundamentally different from culinary use of dried herbs
• The concentrated nature of essential oils means that doses which appear small (e.g., 200 mg) contain vastly more volatile compounds than dietary use of oregano spice
• Emulsified or enteric-coated preparations are preferable to pure essential oil for oral use
• Duration of oral use should generally be limited to 2-6 weeks unless supervised by a qualified practitioner

Clinical Dosage

Standard Dosage Forms

Notes on Dosage

• No clinically validated dosage exists for any specific indication
• Carvacrol content varies widely between products (reported ranges: 30-85%); product standardization to carvacrol content is essential for consistent dosing
• Short-term use (2-6 weeks) is the general recommendation for oral supplementation
• Long-term daily use is not supported by safety data
• Source species matters: Origanum vulgare subsp. hirtum (Greek oregano) typically yields the highest carvacrol content; Mexican oregano (Lippia graveolens) is a different species entirely

Sources

• Chedid V, et al. Herbal therapy is equivalent to rifaximin for the treatment of small intestinal bacterial overgrowth. Glob Adv Health Med. 2014;3(3):16-24
• Force M, et al. Inhibition of enteric parasites by emulsified oil of oregano in vivo. Phytother Res. 2000;14(3):213-214
• Leyva-Lopez N, et al. Essential oils of oregano: biological activity beyond their antimicrobial properties. Molecules. 2017;22(6):989
• Lu M, et al. Bactericidal property of oregano oil against multidrug-resistant clinical isolates. Front Microbiol. 2018;9:2329
• Sharifi-Rad M, et al. Carvacrol and human health: a comprehensive review. Phytother Res. 2018;32(9):1675-1687
• Lambert RJ, et al. A study of the minimum inhibitory concentration and mode of action of oregano essential oil, thymol and carvacrol. J Appl Microbiol. 2001;91(3):453-462
• Baser KHC. Biological and pharmacological activities of carvacrol and carvacrol bearing essential oils. Curr Pharm Des. 2008;14(29):3106-3119
• Llana-Ruiz-Cabello M, et al. In vitro toxicological evaluation of essential oils and their main compounds used in active food packaging: a review. Food Chem Toxicol. 2015;81:9-27
• Zhang Y, et al. Antibacterial activities of oregano essential oils and their active components. Front Pharmacol. 2025;16:1579283

Connections

• Compare with Thyme as a closely related Lamiaceae herb whose essential oil shares carvacrol and thymol as key constituents; thyme has Commission E approval for bronchitis and catarrh (as herb, not essential oil)
• Compare with Tea Tree as another essential oil with strong in vitro antimicrobial activity; tea tree oil has substantially more clinical evidence for topical antimicrobial applications
• Compare with Echinacea as an immune support herb with a much larger clinical trial database; echinacea has Commission E, ESCOP, and EMA monographs
• Compare with Andrographis for upper respiratory infection support; andrographis has stronger clinical evidence for cold symptom reduction